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Background: ERp57 is a disulfide isomerase 
upregulated in Prion related-disorders but its impact 
on PrP biology is unknown. 
Results:  ERp57 gain- and loss-of-function can 
respectively increase or reduce PrP levels in neurons, 
in cell culture and animal models. 
Conclusion: ERp57 regulates steady-state prion 
protein levels.  
Significance: ERp57 is a cellular factor involved in 
the folding and quality control of PrP, representing a 
novel therapeutic target in Prion-related diseases. 
 
ABSTRACT 
Although the accumulation of a misfolded 
and protease-resistant form of the prion protein 
(PrP) is a key event in Prion pathogenesis, the 
cellular factors involved in its folding and quality 
control are poorly understood. PrP is a 
glycosylated and disulfide-bonded protein 
synthesized at the endoplasmic reticulum (ER). 
The ER foldase ERp57 (also known as Grp58) is 
highly expressed in the brain of sporadic and 
infectious forms of Prion-related disorders. ERp57 
is a disulfide isomerase involved in the folding of a 
subset of glycoproteins in the ER as part of the 
calnexin/calreticulin cycle. Here we show that 
levels of ERp57 increase mainly in neurons of 
Creutzfeldt-Jacob patients. Using gain- and loss-of-
function approaches in cell culture we demonstrate 
that ERp57 expression directly controls the 
maturation and total levels of wild-type PrP and 
mutant forms associated with human disease. In 
addition, we found that PrP physically interacts 
with ERp57, and also with the closest family 
member PDIA1, but not ERp72. Furthermore, we 
generated a conditional knockout mouse for 
ERp57 in the nervous system and detected a 
reduction in the steady-state levels of the mono- 
and non-glycosylated forms of PrP in the brain. In 
contrast, ERp57 transgenic mice showed increased 
levels of endogenous PrP. Unexpectedly, ERp57 
expression did not affect the susceptibility of cells 
to ER stress in vitro and in vivo. This study 
identifies ERp57 as a new modulator of PrP levels 
and may help understanding the consequences of 
ERp57 upregulation observed in human disease. 
Prion-related disorders (PrDs) are fatal and rare 
neurodegenerative disorders characterized by 
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spongiform degeneration of the brain accompanied by 
the accumulation of a misfolded form of the prion 
protein (PrP) (1). PrDs can be classified as sporadic, 
familiar and infectious forms, affecting both humans 
and other mammals, where Creutzfeldt-Jacob disease 
(CJD) is the most frequent form in humans. The 
“protein-only” hypothesis postulates that the 
pathogenesis of infectious PrD forms involves a 
conformational change of wild-type PrP (here referred 
to as PrPC) to a protease-resistant form (PrPRES), 
initiated by a direct interaction between the two PrP 
forms (2). In infectious forms of the disease, PrP 
misfolding occurs mainly in the plasma membrane 
and in the endocytic pathway, whereas in familial 
forms the pathological changes in the conformation of 
PrP are proposed to occur during its synthesis at the 
endoplasmic reticulum (ER)  (reviewed in (3)).  
Human PrPC biosynthesis involves a series of post-
translational modifications including the addition of 
N-linked glycosylations at Asn181 and Asn197, the 
formation of a disulfide bridge between Cys179 and 
Cys214, and the addition of a GPI anchor at Ser230, 
among other post-translational modifications (1, 4). 
About 10% of PrPC is not properly folded at the ER 
and is removed by the proteasome through the ER-
associated degradation (ERAD) pathway (5, 6). Once 
folded, PrPC is transported to the plasma membrane 
where it locates mainly to lipid raft microdomains via 
its GPI anchor (4, 7). Although PrP misfolding is the 
triggering step initiating PrDs, the cellular factors 
involved in the folding/misfolding of PrP are 
unknown. 
Different reports have shown that the 
accumulation of misfolded PrP induces ER stress in 
infectious PrD forms (8–16), while in familial forms 
of PrDs the involvement of protein folding stress 
responses is less clear (17–19). ER stress triggers an 
adaptive reaction known as the unfolded protein 
response (UPR), which controls the expression of a 
diverse group of target genes involved in protein 
folding, quality control mechanisms and ERAD (20, 
21). When these pro-survival mechanisms are unable 
to recover ER proteostasis, the UPR triggers apoptosis 
(22). ER stress has been proposed to have two main 
consequences on PrD progression, (i) it may 
contribute to the neurological impairment due to the 
repression of the synthesis of a cluster of synaptic 
proteins (11, 12), and (ii) it may operate as a signal to 
trigger neuronal loss (9). In vitro experiments have 
shown that a vicious cycle may operate in prion 
pathogenesis where prion misfolding predisposes cells 
to ER stress, which then may facilitate partial 
misfolding of PrPC and, thus, prion replication (15, 
23–26). Importantly, ER stress is also emerging as a 
driver of most common neurodegenerative diseases 
including Alzheimer´s disease, Parkinson and ALS 
(27).  
A proteomic study of sporadic CJD brain 
tissue revealed that the major protein upregulated in 
this pathology is the ER foldase ERp57 (also known 
as Grp58 or PDIA3) (28). This observation was then 
confirmed in sporadic, but also new variant CJD 
cases, in addition to animal models of infectious PrD 
(8–10, 13, 14, 18, 23). ERp57 is a member of the 
protein disulfide isomerase (PDI) family, a group of 
around 21 proteins that catalyze the formation and 
isomerization of disulfide bonds thereby facilitating 
protein folding (29). Accumulating evidence support a 
functional role of PDIs in a variety of protein 
misfolding disorders affecting the nervous system 
(30). ERp57 is a central component of the calnexin 
(CNX) and calreticulin (CRT) cycle, involved in the 
folding and quality control of a subgroup of 
glycoproteins in the ER (31, 32). Although genetic 
ablation of ERp57 expression in mice is 
embryonically lethal (33, 34), Erp57 deficient cells do 
not develop drastic alterations in the folding of 
glycosylated proteins and only a small subgroup of 
putative substrates are affected (35, 36). Beside its 
role in the CNX and CRT cycle, ERp57 is required as 
a scaffold protein for the assembly of the heavy chain 
of the MHC class I peptide loading complex, a 
function independent of its enzymatic activity 
involving covalent bonding with tapasin (37–39). 
Additional functions for ERp57 are reported, 
including the modulation of ER calcium homeostasis 
and STAT3 signaling (34, 40, 41). Although PDIs 
have been proposed to have neuroprotective activities 
(30), a drug screening identified a pro-apoptotic role 
of ERp57 and PDIA1 in models of neurodegeneration 
(42).  
Only few studies have attempted to address 
the impact of ERp57 in PrDs. Using cell culture 
experiments we showed that ERp57 expression 
protects cells against the toxicity of infectious PrP 
forms (10). An interactome analysis indicated that 
PrPC physically associates with ERp57, and 
pharmacological inhibition of PDI activity increased 
the levels of prion replication in vitro (10, 43). PrPC 
also binds to CNX and CRT (44). Expression of 
PDIA1, the closest family member to ERp57, is also 
induced in PrD rodent models. PDIA1 expression has 
protective effects against mutant PrP associated with 
human disease, reducing ER stress levels (18). In vitro 
studies also suggested that disulfide bonds may 
contribute to PrP misfolding and aggregation (45–49). 
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Based on this evidence, here we investigate the 
possible impact of ERp57 in the expression of PrP 
using gain- and loss-of-function approaches both in 
cell culture models and genetically modified mice. 
Our results support an active involvement of ERp57 in 
the fine-tuning of the protein levels of PrP. 
 
EXPERIMENTAL PROCEDURES  
Human samples - The study was conducted according 
to the provisions of the Helsinki Declaration, and was 
designed in accordance with the relevant Chilean 
legislation and carried out with the approval of the 
Ethics Committee of the El Salvador Hospital, 
Santiago, Chile. Autopsies and human sample use 
were approved by the Ethics Committee of the Faculty 
of Medicine of University of Chile and by the 
FONDECYT funding agency (protocol number CBA 
#0323 FMUCH).  
 
Histological analysis - For histological analysis of 
human tissue, 10 µm thick sections were obtained 
from formalin fixed, paraffin-embedded blocks of the 
brains of CJD and control patients. The paraﬃn-
embedded sections were deparaffinized in xylene, 
followed by rehydration in a decreasing concentration 
of ethanol solutions. For routine pathological 
examination, deparaffinized sections from all blocks 
were stained with hematoxylin and eosin. Sections for 
immunohistochemistry (IHC) were incubated in 10 
mM sodium citrate buffer (pH 6.0) and heated three 
times in a microwave oven for 5 min for antigen 
recovery, washed in TBS IHC wash buffer, treated 
with formic acid for 5 min, and washed again. 
Sections were then pretreated with 0.3% H2O2 in 
methanol for 30 min at room temperature to inhibit 
endogenous peroxidase activity. After washing twice 
with TBS IHC wash buffer for 5 min each, sections 
were blocked with 3% normal horse serum for 30 min 
at room temperature, followed by incubation with 
anti-ERp57 (1:100, Santa Cruz Biotechnology), anti-
PDIA1 (1:100, Abcam), anti-ERp72 (1:100, 
Stressgen), anti-KDEL (1:100, Stressgen), and anti-
PrP 6D11 (1:500, SIGNET) in a humidified chamber 
at 4° C overnight. Negative control sections were 
incubated with a negative control reagent (Dako) 
instead of primary antibodies. After washing twice 
with TBS IHC wash buffer for a total time of 5 min, 
the sections were incubated with the respective 
biotinylated secondary antibody for 30 min at room 
temperature, rinsed twice with TBS IHC wash buffer 
for a total of 5 min, followed by incubation with the 
avidin-biotin ABC kit (Vector Laboratories) for 30 
min at room temperature. After rinsing with TBS IHC 
wash buffer, peroxidase labeling was visualized with 
DAB (Impact DAB, Vector Laboratories) for 3 min at 
room temperature. Sections were then rinsed in tap 
water, dehydrated for 10 min, cleared and mounted. 
For histological analysis of mouse tissue, 
animals were anesthetized using ketamine/xylazine 
and perfused intracardially with ice-cold saline 
followed by 4% paraformaldehyde (PFA) in PBS (pH 
7.4). After 24 h post-fixation in 4% PFA, brains were 
cryoprotected in 30% sucrose in PBS. Twenty-five 
micrometer thick coronal brain sections were obtained 
using a Leica cryostat (Leica, Nussloch, Germany). 
Sections were pretreated with 3% H2O2 in methanol 
for 30 min at room temperature followed by 
incubation in citrate buffer (pH 6.0) for 15 min at 95 
ºC for antigen recovery. After two washes in PBS for 
5 min each, sections were blocked with 5% BSA, 
0.3% Triton X-100 in PBS for 1 h at room 
temperature followed by incubation with anti-NeuN 
(1:300, Millipore) and anti-GFAP (1:250, Dako), or 
anti-ERp57 (1:100, Santa Cruz Biotechnology) in a 
humidified chamber at 4ºC overnight. After washing 
three times in PBS, sections were incubated with goat 
anti-mouse IgG Alexa Fluor 594 and goat anti-rabbit 
IgG Alexa Flour 488 (1:1000, Invitrogen) or HRP-
conjugated goat anti-rabbit IgG (1:1000, Invitrogen) 
secondary antibodies for 1 h at room temperature. 
Immunohistochemistry was performed using DAB 
HRP substrate kit (Vector Laboratories) using 
manufacturer’s instructions. 
 
Cell culture, plasmids and cell transfections – 
Murine embryonic fibroblasts (MEFs), HEK293T, 
Neuro2a and NSC34 cells were cultured in DMEM 
supplemented with 10% fetal bovine serum and 
antibiotics (10,000 U/ml Penicillin, 10 µg/ml 
streptomycin), at 37°C and 5% CO2. Transfections 
were performed using Effectene (Qiagen) according to 
manufacturer’s instructions. Expression vectors of 
3F4-tagged PrP mutants (PrPCTM, PrPPG14, PrPD177N 
and PrPE199K) and GFP fusion proteins were provided 
by David Harris (Washington University, USA) (50). 
The generation of PrPC-3F4 and PrPC-GFP constructs 
was previously described (26). The construct 
encoding GFP-tagged amyloid precursor protein 
(APP-GFP) was a gift from Patricia Burgos 
(Universidad Austral de Chile, Chile) (51). Plasmids 
to express PDIA1, ERp57 and ERp72 tagged with the 
V5 epitope were provided by Dr. Neil Bulleid 
(University of Glasgow, Scotland) (52). The KDEL-
DsRED was obtained from Clontech Laboratories 
(Mountain View, CA, USA). Lentiviral expression 
vector pLKO.1 carrying shRNA against ERp57 (target 
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sequence 5’-GACCAGTTTATGTTTGTGGTT-3’) or 
luciferase (for Mock control) were from The Broad 
Institute (Boston, MA, USA). Lentiviral particles 
were generated by standard methods and biosafety 
rules using HEK293T cells (53, 54). Stable 
knockdown of ERp57 (and Mock control) in Neuro2a 
cells was performed by lentiviral transduction of 
constructs encoding shRNA for ERp57 (or luciferase) 
followed by selection with puromycin. NSC34 cells 
stably expressing ERp57 were generated by 
transfection using Effectene (Qiagen) following the 
manufacturer’s instructions. After 48 h of transfection, 
cells were selected using G418 (1.3 mg/ml).  
 
SDS-PAGE and Western blot analysis – Cell culture 
pellets or brain tissue was homogenized on ice in 
RIPA buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 
0.1% SDS, 0.5% DOC, 0.5% Triton X-100) 
containing a protease inhibitor cocktail (Roche, Basel, 
Switzerland). Protein concentrations were determined 
by micro-BCA assay (Pierce, Rockford, IL, USA). 
The equivalent of 30–50 g of total protein was 
generally loaded onto 10% SDS-PAGE gels and 
analyzed by Western blot. The following antibodies 
and dilutions were used: anti-PrP (6D11) (1:5000, 
SIGNET), anti-PrP (3F4) (1:5000, Abcam), anti-
ERp57 (1:2000, Santa Cruz Biotechnology), anti-
PDIA1 (1:3000, Abcam), anti-ERO1L (1:2000, 
Novus Biologicals), anti-calnexin (1:2000, Stressgen),  
anti-BiP, (1:3000, Abcam), anti-β-Actin (1:2000, Cell 
Signaling), anti-Hsp90 (1:3000, Santa Cruz 
Biotechnology), and anti-V5 (1:5000, Invitrogen). 
After the incubation with the primary antibody, 
membranes were incubated for 1h at room 
temperature with HRP-conjugated secondary 
antibodies (all from Invitrogen). After washing, 
detection was performed by enhanced 
chemiluminescence assay (Amersham Biosciences, 
Cardiff, UK). 
RNA extraction and quantitative real-time PCR - 
Total RNA from tissues was isolated using Trizol as 
recommended by the supplier (Life Technologies, 
15596-018). The cDNA was synthesized with 
SuperScript III reverse transcriptase (Life 
Technologies, 11754250) using random primers 
p(dN)6 (Roche). Quantitative PCR reactions were 
performed using standard protocols (55). Actin 
mRNA was monitored as a housekeeping control.  
The following primers were used for Erp57: forward 
5’-GAGGCTTGCCCCTGA-GTATG-3’and reverse 
5’-GTTGGCAGTGCAATCC-ACC -3’. Xbp1s: 
forward 5’-TGCTGAGTCCGC-AGCAGGTG-3’ and 
reverse 5’-GACTAGCAGACT-CTGGGGAAG-3’. 
Prp: forward 5’-TCATCCCACGATCAGGAAGAT-
3’ and reverse 5’-TGCGTCACCCAGTACCAGAA-
3’. Edem: forward 5’-
AAGCCCTCTGGAACTTGCG-3’ and reverse 5’- 
AACCCAATGGCCTGTCTGG-3’. Bip: forward 5’- 
TCATCGGACGCACTTGGAA-3’ and reverse 5’- 
CAACCACCTTGAATGGCAAGA-3’. Pdia1: 
forward 5’-AGTT-CGCCCCAACCAGTACTT-3’ 
and reverse 5’-CAAGATCAAGCCCCACCTGAT-3’. 
Chop: forward 5’-GTCCCTAGCTTGGCTGACAGA-
3’ and reverse 5’-TGGAGAGCGAGGGCTTTG’. 
Actin: forward 5’-
CTCAGGAGGAGCAATGATCTTGAT-3’ and 
reverse 5’-TACCACCATGTACCCAGGCA-3’. 
Splicing of XBP1 mRNA was also evaluated by 
conventional PCR using the primers Xbp1: forward 
5’- ACACGCTTGGGAATGGACAC-3’ and reverse 
5’- CCATGGGAAGATGTTCTGGG-3’, or by 
conventional PCR using the primers Xbp1: forward 5'-
AAACAGAGTAGCAGCGCAGACTGC-3' and 
reverse 5'-
GGATCTCTAAAACTAGAGGCTTGGTG-3' 
followed by digestion with the restriction enzyme PstI 
as described previously (56).  
Proteinase K (PK), Filter-trap, and PNGase F 
experiments - PK assays were performed using a 
protocol previously described (26). Twenty 
micrograms of total protein in 1% NP40 buffer were 
treated for 30 min at 37°C with different 
concentrations of PK (2, 4 and 6 µg/ml). Proteolysis 
was stopped by adding phenylmethylsulfonyl fluoride 
followed by SDS-PAGE sample buffer; then heating 
the samples for 5 min at 95°C. For Filter-trap, 25 µg 
of total protein in 1% NP40 buffer was diluted in PBS 
containing 1% SDS to a final concentration of 0.25 
µg/µl and filtered through cellulose acetate membrane 
with a pore size of 0.22 µm in a dot-blot apparatus 
(Bio-Rad, CA, USA). For loading control, 25 µg of 
total protein was analyzed by SDS-PAGE and 
Western blot or, in addition, diluted in PBS and 
loaded onto PVDF membrane in a dot-blot apparatus 
followed by Ponceau S staining. For deglycosylation 
assays, samples were treated with N-glycosidase F 
(PNGase F) (New England Biolabs) following 
manufacturer's recommendations. Briefly, samples 
were cooled to 25°C, and then the reaction buffer and 
10 U of PNGase F were added. After 1 h at 37°C, 
SDS-PAGE sample buffer was added and samples 
were heated for 5 min at 95°C followed by 
electrophoresis. Finally, samples were analyzed by 
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Western blot using the anti-PrP (6D11) or (3F4) 
antibodies. 
Pulse and chase experiments - Eighteen hours after 
transfection with expression vectors for 3F4-tagged 
PrP, MEFs were starved for 15 min in Met/Cys free 
medium, pulsed for 10 min with 50 μCi [35S]Met/Cys 
in 1 ml starvation medium/dish, and chased for the 
indicated times with DMEM supplemented with 5 
mM ‘cold’ Met/Cys. Post-nuclear supernatants (PNS) 
were prepared by solubilization of cells in 800 μl/dish 
ice-cold 2% CHAPS in HEPES-buffered saline 
(HBS), pH 6.8, containing 20 mM N-ethylmaleimide 
and protease inhibitors. CHAPS-insoluble material 
was separated by 10-min centrifugation at 10,000 × g. 
Immunoprecipitations were performed by adding 
protein A beads (Sigma; 1:10, w/v swollen in HBS) 
and the anti-PrP (3F4) antibody to the cleared extract 
followed by incubation for 2 h at 4°C. 
Immunoprecipitates were extensively washed three 
times with 0.5% CHAPS in HBS and resuspended in 
sample buffer for SDS-PAGE. Relevant bands were 
quantified using the ImageQuant software (Molecular 
Dynamics, Sunnyvale, CA). Gels were also exposed 
to BioMax films (Eastman-Kodak, Rochester, NY) 
and scanned with an AGFA scanner (Mortsel, 
Belgium).  
Cycloheximide (CHX)-chase experiments 
were performed in MEFs transfected with PrP-GFP or 
APP-GFP constructs. Briefly, after 24 h of 
transfection cells were re-plated in a 48-well format 
and then 24 h later treated with 50 µg/ml of CHX for 
different time points. After the treatment, cells were 
detached by trypsinization and analyzed by flow 
cytometry. 
Immunoprecipitations - HEK293T cells were 
transfected using Effectene transfection reagent. After 
48 h, cells were collected and washed once in 1 ml of 
PBS pH 7.4. Subsequently, cells were resuspended in 
500 µl of NP-40 buffer (0.2% NP-40, 50mM Tris-HCl 
pH7.5 , 150 mM NaCl ) plus a protease inhibitor mix 
(Roche) and incubated overnight at 4 °C. Cell lysate 
was centrifuged at 10,000 rpm for 5 min at 4 °C. 
Subsequently, the supernatant was incubated with V5 
antibody-coated agarose beads (V5 protein 
purification kit, MBL International) under constant 
agitation for 4 h at 4 °C. Then, the beads were washed 
3 times with NP-40 buffer and the antibody-bound 
complexes were released by incubation with V5 
peptide (MBL International) for 30 min at room 
temperature. Finally, the supernatant was obtained by 
centrifugation and analyzed by Western blot. 
 
Generation of conditional ERp57 knockout mice - 
The ERp57 floxed mice were previously described 
where exons 2 and 3 were flanked with two loxP sites 
(33) and were kindly provided by Dr. Günther 
Hämmerling (German Cancer Research Center, 
Heidelberg, Germany). Mice expressing Cre 
recombinase under the control of the nestin promoter 
were obtained from The Jackson Laboratory (B6.Cg- 
Tg(Nes-cre)1Kln/J, 003771). To generate mice 
deficient in ERp57 in the central nervous system 
(CNS), ERp57 floxed animals were crossed with 
Nestin-Cre transgenic mice as we described before 
(8). Mice genotypes were designated as follows: 
ERp57WT (wild-type), ERp57HET (heterozygous, 
carrying one knockout allele), ERp57KO (conditional 
knockout). All experiments and animal care follow the 
Institutional Review Board´s Animal Care of the 
University of Chile (CBA # 0305 FMUCH). The 
following primers were used for genotyping of mice: 
Erp57 floxed allele, forward 5’-
CGCCAGCCTCTCCATTTAG -3’; Erp57 floxed 
allele reverse 5’-CAGAGATCCTGCCTCTG -3’, Cre 
forward 5’-GCGGTCTGGCAGTAAAAACTATC -3’ 
and Cre reverse 5’-GTGAAACAGCATTGCTGT-
CACTT -3’. 
 
Generation of ERp57 transgenic mouse model – The 
transgenic mouse line overexpressing ERp57 was 
recently described (57) using the expression plasmid 
MoPrP.XhoI (58). In brief, the human ERp57 cDNA 
(Gene ID: 2923) was introduced into the plasmid 
using the XhoI restriction site. The resulting plasmid 
expressing the ERp57 sequence under the control of 
the PrP promoter was used to generate transgenic 
mice at the “Centro de Estudios Científicos” (CECS), 
Valdivia, Chile. The plasmid was purified and 
linearized for microinjection in mice with a FVB 
background. The primers used for genotyping were: 
forward 5’-AATTCCTGGATGCTGGGCAC-AAAC-
3’ and reverse 5’-TCTGCTTGTCATCGT-
CGTCCTTGT-3’. Selected transgenic mouse lines 
were backcrossed into C57BL/6 background for more 
than 10 generations. All experiments and animal care 
followed the Institutional Review Board´s Animal 
Care of the University of Chile (CBA #0305 
FMUCH). 
 
Pharmacological induction of ER stress – For 
induction of ER stress in vitro, the ER stressors 
tunicamycin, thapsigargin, or brefeldin A were added 
to the cell culture medium followed by the 
measurement of ER stress markers by Western blot or 
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quantitative real-time PCR analysis as we previously 
reported  (56, 59). The MTT method was employed to 
measure cell viability according to manufacturer’s 
instructions (Promega). For induction of ER stress in 
vivo, mice received a single intraperitoneal injection 
of tunicamycin (5 mg/kg) diluted in sterile 150 mM 
glucose solution as described before (60). Control 
mice received intraperitoneal injection of vehicle (5% 
DMSO in 150 mM glucose solution). Mice were 
euthanized and tissue collected 24 h after injection. 
Statistical analysis - For statistical analysis Graph Pad 
Prism Software Version 5.01 and SigmaPlot were 
used. All graphs show mean with SEM. Significance 
was calculated using Student’s t-test or one-way or 
two-way ANOVA with Bonferroni post hoc test.  
 
RESULTS 
 
ERp57 levels are increased in neurons of CJD 
patients. Although it is reported that ERp57 levels are 
augmented in postmortem brain tissue derived from 
CJD patients (9, 28), the specific cell types responding 
have not been defined. To analyze the expression 
pattern of ERp57 in the brain, we performed 
immunohistochemistry studies. We confirmed the 
diagnosis of CJD patients by H&E staining and 
immunohistochemistry of PrP. The three subjects 
analyzed presented signs of spongiosis, neuronal loss, 
and gliosis (Fig. 1A and B). We then evaluated the 
expression pattern of ERp57 in the cerebellum using 
immunohistochemistry and found higher ERp57 
levels in Purkinje cells of CJD patients compared to 
control subjects (Fig. 1C). We also monitored the 
expression levels of other ER chaperones in these 
patient samples. Analysis of PDIA1 distribution, the 
closest homologue to ERp57, also revealed to 
different extents an upregulation in CJD cases, 
whereas ERp72 did not show clear changes compared 
with control subjects (Fig. 1D). KDEL staining, which 
mostly recognizes BiP/Grp78 and Grp94, depicted a 
slight increase in some of the CJD cases analyzed 
with variable results. These results confirmed 
previous findings supporting the upregulation of 
ERp57 levels in postmortem brain tissue derived from 
CJD cases. 
 
ERp57 deficiency reduces PrP levels. Since ERp57 
selectively catalyzes the folding and disulfide bond 
formation of a subset of glycosylated proteins, we 
decided to analyze the expression levels of 
endogenous PrPC in murine embryonic fibroblasts 
(MEFs) that are deficient for ERp57 (ERp57KO) (36). 
We observed a reduction in the steady-state levels of 
PrPC in ERp57KO cells when compared with wild-type 
control cells by Western blot analysis (Fig. 2A). 
Quantification of relative PrPC levels in ERp57KO 
MEFs indicated a reduction near 25% (Fig. 2A, right 
panel). To confirm these results in a different cell 
culture system, we knocked down ERp57 in Neuro2a 
cells after stable delivery of a shRNA construct using 
lentiviral vectors. A control shRNA against luciferase 
mRNA was employed (Mock). Targeting ERp57 
resulted in significant reduction of PrPC steady-state 
levels (Fig. 2B).  
We then tested the effects of ERp57 
deficiency on the levels of a mutant PrP form linked 
to CJD. We transiently transfected ERp57KO and 
control MEFs with expression vectors for PrPC or the 
murine PrPD177N variant, equivalent to human 
mutation D178N linked to CJD, in addition to empty 
vector (Mock). All proteins contained the 3F4 tag to 
differentiate them from the endogenous protein. We 
then determined PrP levels using the anti-PrP 3F4 
antibody and observed that ERp57 deficiency resulted 
in lower levels of both PrP forms (Fig. 2C). To 
corroborate these findings, ERp57KO MEFs were 
transiently transfected with PrP-GFP fusion constructs 
(PrPC-GFP and PrPD177N-GFP) and the percentage of 
cells expressing GFP and the relative florescence 
intensity were quantified by flow cytometry analysis 
(Fig. 2D). Transfection of a GFP plasmid alone 
showed similar expression in both ERp57 WT and KO 
cells (Fig. 2D). Again, ERp57 deficiency significantly 
reduced the levels of wild-type and mutant PrP fused 
to GFP.  
We then performed control experiments to 
determine if changes in PrP observed in ERp57KO 
cells are due to a generalized deficit in protein folding 
in the ER. Thus, we overexpressed amyloid precursor 
protein (APP) fused to GFP (APP-GFP), another 
protein that traffics through the secretory pathway that 
undergoes glycosylation. We monitored the levels and 
distribution of APP using flow cytometry and 
fluorescent microscopy analysis and did not observe 
changes in APP-GFP levels or expression pattern 
when ERp57WT and ERp57KO MEFs were compared 
(Fig. 2E). These results suggest that ERp57 deficiency 
may affect client proteins, such as PrP, in a more 
specific manner. 
Although mutant PrP forms associated with 
familial PrDs are retained at the ER, data linking their 
expression with the induction of an ER stress response 
is controversial (17–19). To study the impact of 
mutant PrP on ER physiology, we expressed in 
Neuro2a cells the murine PrPD177N variant, PrPPG14 
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(nine-octapeptide insertion) linked to Fatal Familial 
Insomnia (FFI), PrPE199K (equivalent to human 
PrPE200K) associated with familial CJD, and the point 
mutant L9R/3AV that generates an abnormal 
pathogenic form called PrPCTM (carboxy-terminal 
mutant) (61–63). All constructs contained the human 
PrP-3F4 epitope for detection (50) (Fig. 2F). These 
mutants were selected because of previous studies 
showing their partial retention at the ER and Golgi 
compartments (50, 64, 65). Unexpectedly, expression 
of all these mutant PrP forms did not trigger the 
upregulation of ERp57 at the protein (Fig. 2F, upper 
panel) or mRNA level (Fig. 2F, lower panel).  
Similarly, analysis of XBP1 mRNA splicing, a 
classical marker of ER stress (22), did not reveal any 
changes upon mutant PrP expression (Fig. 2G). We 
then tested whether mutant PrP overexpression could 
enhance the induction of ERp57 after treatment with 
the pharmacological ER stress agent thapsigargin. 
Again, the upregulation of Erp57 or spliced Xbp1 
mRNA were not altered in Neuro2a cells expressing 
wild-type or mutant PrP (Fig. 2H). In summary, our 
results suggest that PrD-linked mutant PrP does not 
trigger the upregulation of ERp57 but under resting 
conditions ERp57 controls PrP steady-state levels. 
 
ERp57 overexpression enhances PrP expression. We 
then performed gain-of-function studies by stably 
overexpressing a V5-tagged version of ERp57 (35) in 
the NSC34 neuronal cell line. First, we analyzed the 
expression levels of endogenous murine PrPC by 
Western blot. Consistent with our previous results, 
augmented steady-state levels of PrPC were observed 
in these cells when compared with control Mock cells 
(Fig. 3A). We then assessed the effects of ERp57-V5 
overexpression on the levels of a set of PrP mutants 
linked to PrDs. We confirmed the altered localization 
of these PrP mutants using GFP fusion constructs 
together with the ER marker KDEL-dsRED, 
observing reduced expression at the plasma membrane 
and increased intracellular accumulation (Fig. 3B). 
We then transiently transfected PrP-3F4 constructs in 
NSC34 cells stably overexpressing ERp57-V5 and 
determined the relative expression levels of PrP after 
48 h using Western blot analysis. In agreement with 
our loss-of-function experiments, overexpression of 
ERp57 increased the levels of PrPC and the mutants 
D177N, PG14, and E199K (Fig. 3C). ERp57 had only 
a slight effect on PrPCTM, which had low expression 
levels. We then evaluated the misfolding of PrP in 
these experiments by treating protein extracts with 
different concentrations of proteinase K (PK). 
Consistent with increased levels of PrP upon ERp57-
V5 overexpression, the relative amount of PK-
resistant forms of PrP was also augmented under these 
conditions (Fig. 3D). These observations indicate that 
ERp57 expression modulates steady-state levels of 
PrP wild-type and mutant forms in different cell 
culture models.  
 
ERp57 deficiency alters PrP maturation. Based on 
the observation that ERp57 controls the expression of 
PrP at basal levels, we decided to monitor in detail its 
synthesis and maturation in ERp57KO cells. We 
performed pulse-chase experiments in ERp57KO and 
wild-type MEFs transiently transfected with 3F4-
tagged PrPC. In control ERp57WT cells, the classical 
pattern of PrP maturation was observed over time, 
where non-glycosylated, mono-glycosylated and di-
glycosylated PrP bands were visualized, in addition to 
PrP species with higher molecular weight showing 
more complex glycosylations (Fig. 4A, left panel). 
The nature of these bands was confirmed after the 
treatment of protein extracts with PNGase to 
deglycosylate PrP (Fig. 4B). We then studied the 
synthesis and maturation of PrPC in ERp57-deficient 
cells between 10 and 180 min after radioactive pulse 
(Fig. 4A, right panel). Under these conditions, we 
found a nearly 50% reduction in the average half-life 
of total overexpressed PrPC in ERp57-deficient cells 
(Fig. 4A). Importantly, no differences in the rate of 
PrP synthesis were found between ERp57KO and 
control cells as measured by the PrP-radioactive 
signal when we started the chase (t = 0-10 min) (Fig. 
4A). Surprisingly, the band pattern of PrP in SDS-
PAGE analysis performed without the reducing agent 
DTT in the sample buffer remained the same, 
suggesting the absence of an altered oligomerization 
into S-S linked assemblies in ERp57 deficient cells 
(Fig. 4A, lower panels), which is in contrast to the 
results reported for some ERp57 substrates (36).  
To further assess whether PrP forms protein 
aggregates undetectable by Western blot, we carried 
out filter-trap analysis to evaluate the presence of 
large species that are retained in the 0.22-µm pores of 
the cellulose acetate membrane. Remarkably, we 
observed that ERp57-deficiency in MEFs promote the 
aggregation of endogenous PrP at basal levels (Fig. 
4C). More over these large aggregates were 
susceptible to DTT treatment, suggesting disulfide-
dependent interactions (Fig. 4D). Together these 
results suggest that a reduced folding efficiency of PrP 
in ERp57KO cells that leads to aberrant intermolecular 
disulfide bonds in the protein.    
We then complemented these experiments by 
monitoring the steady-state levels of PrPC-GFP by 
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flow cytometry analysis in cells treated with 
cycloheximide to inhibit protein synthesis. Again, a 
lower stability of PrPC was confirmed in ERp57KO 
MEFs when compared to control cells  (Fig. 4E, upper 
panel). In contrast, APP-GFP showed similar stability 
in both cell lines under the same experimental 
conditions (Fig. 4E, lower panel). Taken together, 
these results suggest that ERp57 may participate in the 
folding or the maturation of PrPC.  
 
ERp57 forms a protein complex with PrP. Based on 
our results showing that ERp57 modulates PrPC levels 
and affects its maturation, we then investigated the 
possible physical interaction between PrPC and 
ERp57. We co-transfected a PrPC-3F4 construct 
together with a V5-tagged version of ERp57 in HEK 
cells. After 48 h, we immunoprecipitated ERp57-V5 
and analyzed the possible association with PrPC using 
Western blot analysis. We observed an interaction 
between ERp57-V5 and PrPC-3F4, where the mono- 
and di-glycosylated forms of PrP were preferentially 
co-immunoprecipitated (Fig. 5A). As control, we then 
analyzed the possible association of PrP with V5-
tagged PDIA1 or ERp72, two structurally related 
proteins to ERp57 (29). Immunoprecipitation of PrPC-
3F4 revealed only an interaction with PDIA1, but not 
with ERp72 (Fig. 5A). We then performed similar 
experiments with the PrPD177N mutant.  We detected 
an association between PrPD177N and ERp57-V5 with a 
similar efficiency of co-immunoprecipitation as PrPC 
(Fig. 5B). However, the di-glycosylated form of 
PrPD177N was enriched in these experiments (Fig. 5B). 
These results suggest that ERp57 and PDIA1 form 
protein complexes with PrP. 
 
ERp57 expression does not influence the 
susceptibility of cells to ER stress. Our results 
together with previous reports suggest that ERp57 
may have a dual activity on PrDs, modulating PrP 
synthesis and the survival of cells under the ER stress 
reaction generated in the disease. Thus, we decided to 
monitor the impact of ERp57 expression on the 
susceptibility of cells to experimental ER stress. 
ERp57KO and control MEFs were treated with the ER 
stress agent tunicamycin (Tm) for 16 h and the 
expression levels of different ER folding components 
were monitored, including ERp57, PDIA1, CNX, 
ERO1L, and BiP. No clear changes were observed 
between genotypes at basal levels or in cells 
undergoing ER stress (Fig. 6A), suggesting the lack of 
clear compensatory changes upon Erp57 deletion. In 
agreement with these results, analysis of cell viability 
in cells treated with three different ER stress agents 
indicated no differential vulnerability of ERp57-
deficient cells (Fig. 6B).  
We then performed similar experiments in 
NSC34 cells overexpressing ERp57-V5. 
Overexpression of ERp57 did not reduce the 
activation of XBP1 mRNA splicing or the 
upregulation of the ER stress pro-apoptotic factor 
Chop in cells treated with tunicamycin (Fig. 6C). 
Consistent with these results, no changes on the levels 
of a panel of ER folding factors was observed in 
ERp57-V5 overexpressing cells at basal levels or after 
treatment with tunicamycin (Fig. 6D). Finally, these 
cells did not shown any protection against ER stress 
when cell viability was monitored with the MTT assay 
after treatment with tunicamycin or thapsigargin (Fig. 
6E). In summary, our results indicate that ERp57 
expression does not influence the global response to 
ER stress, but it has a specific effect on controlling the 
levels of PrP. 
 
The PrP expression pattern is altered in the brain of 
a conditional ERp57 knockout mouse. Although 
ERp57 deficiency in mice is embryonic lethal, a 
viable conditional B cell-specific knockout mouse was 
described before (33). We generated a CNS-specific 
ERp57 knockout mouse by crossing that floxed 
animal with a Cre transgenic mouse under the control 
of the Nestin promoter (Woehlbier and Hetz, 
unpublished). Targeting Erp57 in the nervous system 
bypassed embryonic lethality since we were able to 
generate ERp57 heterozygous (ERp57HET) and 
conditional knockout mice (ERp57cKO). We confirmed 
the reduction of Erp57 expression in both genotypes 
at the mRNA level using real-time PCR with a near 
50% reduction in ERp57HET animals and a complete 
loss of ERp57 mRNA expression in ERp57cKO mice 
(Fig. 7A). These results were then validated in brain 
cortex, hippocampus and cerebellum using Western 
blot analysis (Fig. 7B).  
Next, we evaluated mRNA levels of PrP in 
brain cortex of ERp57-deficient mice (Fig. 7C). 
Despite the slight induction observed in ERp57HET 
animals, deficiency of ERp57 in the nervous system 
had no major impact on transcription of PrP (Fig. 7C). 
Then, the protein pattern of endogenous PrP was 
evaluated in the brain of ERp57-deficient mice (Fig. 
7D). Quantification of different PrP species revealed a 
significant reduction of the mono-glycosylated PrP 
form in the cortex of ERp57cKO mice (Fig. 7E, middle 
panel). We also found a small change in the levels of 
the non-glycosylated PrP form (Fig. 7E, right panel), 
whereas no differences in the levels of the di-
glycosylated form were detected (Fig. 7E, left panel).  
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To assess whether targeting ERp57 in the 
brain alters ER proteostasis, we monitored the mRNA 
levels of a few ER stress-responsive genes including 
Bip, Edem1, Pdi and Chop. Overall no changes where 
observed when the three genotypes were compared 
using cerebellar extracts (Fig. 7F). Similarly, analysis 
of the expression levels of CNX, ERO1L, and BiP 
did not reveal any upregulation in ERp57-deficient 
animals (Figure 7G). Qualitative immunofluorescence 
analysis indicated that ERP57cKO mice do not show 
evident signs of neuronal loss or astrogliosis in CNS 
tissue (Fig. 7H). In summary, this data indicate that 
ERp57 deficiency in the nervous system impacts the 
steady-state levels of PrP expression in vivo. 
 
Overexpression of ERp57 in neurons increases PrP 
expression in vivo. We recently generated a 
transgenic mouse that overexpresses a FLAG-tagged 
version of human ERp57 under the control of the PrP 
promoter (ERp57-Tg) (57). The overexpression of 
ERp57-FLAG in transgenic mice was confirmed in 
the cerebellum using Western blot analysis, observing 
a near 1.5 fold increase in ERp57 levels compared 
with non-transgenic littermates  (Non-Tg) (Fig. 8A). 
The overexpression of ERp57 was also confirmed by 
immunohistochemistry (Fig. 8B). We then monitored 
PrP levels in these brain extracts. Remarkably, a 
significant increase in the total levels of PrP was 
observed in the cerebellum of 2-month-old ERp57-
FLAG transgenic mice (Fig. 8C), whereas the mRNA 
levels of PrP were not altered (Fig. 8D).  
We then monitored the susceptibility of 
ERp57-FLAG overexpressing mice to ER stress. We 
intraperitoneally injected these animals with the ER 
stress agent tunicamycin and then measured the levels 
of the ER stress markers Chop and spliced XBP1 
mRNA in the brain using real-time PCR. Consistent 
with our in vitro experiments, ERp57 overexpression 
did not alter the susceptibility of cells to undergo ER 
stress (Fig. 8E). Taken together, these results suggest 
that enforced expression of ERp57 in the brain 
augments PrP levels.  
 
DISCUSSION 
An increase in the levels of ERp57 has been 
described in diseases such as Alzheimer’s disease, 
amyotrophic lateral sclerosis, Parkinson’s disease, 
Huntington's disease and PrD, among other 
pathologies (reviewed in (30)), although its biological 
significance has remained elusive. The induction of 
ERp57 has been associated with an UPR response due 
to the accumulation of misfolded proteins inside the 
ER, assisting in the folding and quality control of 
glycoproteins as part of the CNX/CRT cycle. Here we 
investigated the impact of ERp57 on PrP biogenesis. 
First, we confirmed the increased levels of ERp57 in 
patients diagnosed with sporadic CJD and identified a 
specific response in neurons. Since PrP is a disulfide 
bond-containing glycoprotein, we hypothesized that 
ERp57 could directly participate in the biosynthesis of 
PrP. Our results show that ERp57 deficiency alters the 
maturation and decreases the levels of both 
endogenous and exogenous PrPC, while ERp57 
overexpression has the opposite effect. In addition, 
similar results were obtained when a panel of disease-
related PrP mutants was expressed, suggesting that 
PrPC and PrP mutant forms are possible clients of the 
ERp57-folding pathway. In agreement with this idea, 
we also established that both PrPC and PrPD177N 
physically interact with ERp57. Furthermore, we 
confirmed that PrPC also associates with PDIA1, but 
not with ERp72. On the other hand, it may be feasible 
that ERp57 and PDIA1 act on different 
conformational pools of unfolded/misfolded PrP, 
since PDIA1 is also part of the ERAD pathway (66) 
and may therefore target unfolded/misfolded PrP 
towards degradation. Of note, a recent report 
suggested that calnexin mediates a novel PrP 
clearance pathway under ER stress termed ‘rapid ER 
stress-induced export’ (RESET) (67). RESET 
involves the export of misfolded GPI proteins to the 
plasma membrane for subsequent degradation by the 
lysosome. It may be interesting to explore in the 
future if ERp57 also modulates the degradation of PrP 
by RESET. 
To investigate the significance of ERp57 on 
the biology of PrP in vivo, we first generated a CNS-
specific ERp57 knockout mouse model. Homozygous 
mice showed a near full loss of ERp57 in the CNS, 
whereas heterozygous animals showed a 50% 
reduction in ERp57 mRNA and protein levels. 
ERp57-deficient animals did not show major changes 
in the levels of the di-glycosylated PrP at steady state; 
however, we confirmed the reduction of the mono- 
and non-glycosylated form of endogenous PrP in 
ERp57 knockout animals. This may be explained by 
the compensatory mechanisms involving CNX and 
CRT. Another possibility is the functional 
replacement of ERp57 by other PDIs in neurons in 
vivo, including PDIA1. Furthermore, we have 
examined PrP levels in transgenic mice 
overexpressing ERp57 under the control of the prion 
promoter. We have recently reported a functional 
characterization of this transgenic line showing that 
overexpression of ERp57 improves recovery in 
peripheral nerve regeneration after mechanical injury 
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to sciatic nerve (57), indicating that the overexpressed 
chaperone is functional in the nervous system. 
Interestingly, PrP expression is induced in models of 
peripheral nerve degeneration (68), and its deficiency 
triggers myelin defects (69). Since mice 
overexpressing ERp57 displayed augmented levels of 
PrP in the nervous system, it remains to be determined 
if part of the beneficial effects of overexpressing 
ERp57 are due to enhancement of PrP expression.  
Although ERp57 and PDIA1 have been 
suggested to protect cells against ER stress (70) due to 
its crucial role in assisting the folding of glycosylated 
proteins, we did not find evidence supporting a major 
role of ERp57 in the susceptibility of cells to ER 
stress and cell death in vitro and in vivo using multiple 
experimental systems. These observations may be 
explained by the fact that ERp57 may only catalyze 
the folding of a small subset of glycosylated proteins 
in the secretory pathway (34–36). The expression of 
other PDI family members may maintain the global 
homeostasis of disulfide bond formation at the ER in 
neurons lacking ERp57 expression. Unexpectedly, we 
did not observe drastic compensatory changes in other 
PDIs or ER foldases when ERp57 expression was 
targeted, which again support the concept that ERp57 
may assist the folding of a small subset of ER clients 
proteins and its deficiency does not cause a general 
perturbation of redox folding in the ER. 
In future experiments, we plan to investigate 
if ERp57 modulates the progression of prion disease 
in infectious and genetic models of PrD. Overall, this 
study identifies a new component regulating PrP 
levels that may have relevance to understand the 
contribution of the cellular context during prion 
pathogenesis. 
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ABBREVIATIONS 
 
The abbreviations used are: PrP, prion protein; PrPC, wild-type PrP; PrPRES, protease-resistant PrP; PrDs, Prion-
related Disorders; PDI, protein disulfide isomerase; CNS, Central Nervous System; CJD, Creutzfeldt-Jacob 
Diseases; FFI, Fatal Familial Insomnia; ALS, Amyotrophic Lateral Sclerosis; CNX, Calnexin; CRT, 
Calreticulin; MEFs, Murine Embryonic Fibroblast; ER, Endoplasmic Reticulum; UPR, unfolded protein 
response; ERAD, ER-associated degradation; PK, proteinase K; RESET, rapid ER stress-induced export; APP, 
amyloid precursor protein; Tm, tunicamycin; Thp, thapsigargin; Bref A, brefeldin A; CHX, cycloheximide; TBS, 
Tris-buffered saline; PBS, phosphate-buffered saline; HBS, HEPES-buffered saline; PFA, paraformaldehyde; 
BSA, bovine serum albumin. 
 
 
FIGURE LEGENDS 
 
FIGURE 1. Detection of ERp57 in brain tissue of patients with Creutzfeldt-Jakob disease. (A-D) Brain 
tissue of three CJD patients and three control subjects were fixed in formalin. After a month of fixation, tissue 
was embedded in paraffin and cut into 10 µm thick slices. Cerebral tissues were then (A) stained with 
hematoxylin and eosin (H&E), (B) processed for immunohistochemistry using anti-PrP (3F4) antibody in cortex, 
or (C) anti-ERp57, and (D) anti-PDIA1, anti-ERp72, anti-KDEL antibodies in cerebellum. Black arrows indicate 
positive reaction to ERp57 in Purkinje cells. Scale bars represent 50 m. 
 
FIGURE 2. PrP levels in ERp57-deficient cells. (A) Endogenous levels of PrP in ERp57-deficient (ERp57KO) 
and wild-type control (ERp57WT) MEFs were evaluated by Western blot (left panel) using the anti-PrP (6D11) 
antibody. Quantification of three independent experiments (right panel) was performed. Hsp90 levels were 
monitored as a loading control. (B) Detection of endogenous levels of PrP in Neuro2a cells stably knocked down 
for ERp57. Neuro2a cells stably expressing shRNA against luciferase was used as control (Mock). β-actin was 
monitored as a loading control. (C) ERp57-deficient and wild-type control MEFs were transfected with 3F4-
tagged PrPC or PrPD177N constructs. After 48 h, PrP levels were analyzed by Western blot using the anti-PrP 
(3F4) antibody. Hsp90 was used as a loading control. (D) ERp57-deficient and wild-type control MEFs were 
transfected with PrPC-GFP or PrPD177N-GFP constructs. After 48 h, GFP fluorescence was analyzed by flow 
cytometry. Three independent experiments were performed. (E) ERp57-deficient and wild-type MEFs were 
transfected with a construct encoding GFP-tagged amyloid precursor protein (APP-GFP). After 48 h, cells were 
analyzed by flow cytometry (left panel) or fluorescence microscopy (right panel). (F) Neuro2a cells were 
transfected with constructs encoding 3F4-tagged PrPC or its PrDs-related mutants. Transfection with the empty 
vector was used as control (Mock). After 48 h, protein (upper panel) and mRNA (lower panel) levels of 
endogenous ERp57 were measured by Western blot and real-time PCR, respectively. (G) The level of spliced 
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XBP1 mRNA were monitored in Neuro2a cells overexpressing PrPC or its PrDs-related mutants described in (F) 
using an PstI and RT-PCR based assay (upper panel) or real-time PCR to specifically amplify the spliced variant 
(lower panel). (H) Neuro2a cells were transfected with constructs encoding 3F4-tagged PrPC or PrPD177N and 48 
h later treated with different concentrations of thapsigargin (Thg). After 16 h of treatment, levels of Erp57 
(upper panel) and Xbp1s (lower panel) mRNA were measured by real-time PCR. Bars in panels F, G, and H 
indicate average and standard deviation of three determinations. When indicated, statistical analysis was 
performed using Student’s t-test in panel (A) and one-way ANOVA with Bonferroni post hoc test in panel (D). 
Mean ± SEM with p values: n.s., p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. Densitometric analyses were 
performed using Image J.   
 
FIGURE 3. Endogenous PrP levels in NSC34 cells overexpressing ERp57. (A) NSC34 cells were transfected 
with empty vector (pcDNA3, Mock) or an ERp57 expression vector. After 24 h of transfection, cells were 
selected with the antibiotic G418 for two weeks. Then, ERp57 and endogenous PrP levels were analyzed by 
Western blot. β-actin was used as a loading control. (B) NSC34 cells were transiently co-transfected with 
different PrP-GFP constructs (PrPC-GFP, PrPCTM-GFP, PrPD177N-GFP or PrPPG14-GFP) together with vector 
encoding for the ER marker KDEL-dsRED (red). Localization of PrP (green) was analyzed by confocal 
microscopy. The nucleus was stained with Hoechst (blue). (C) NSC34 cells stably overexpressing ERp57 were 
transiently transfected with constructs encoding 3F4-tagged PrPc and its PrDs-related mutants (PrPCTM, PrPD177N, 
PrPPG14, and PrPE199K). After 48 h, the steady-state levels of PrP were analyzed by Western blot using the anti-
PrP (3F4) antibody. Hsp90 was monitored as a loading control. (D) Proteinase K (PK) resistance of PrPC and 
PrPD177N was assessed in protein extracts from NSC34 cells transiently co-expressing ERp57 for 48 h by 
incubation with the indicated amounts of the protease for 30 min at 37°C followed by Western blot analysis.  
 
FIGURE 4. Pulse-chase assays of PrP in ERp57-deficient MEFs. (A) ERp57 deficient (ERp57KO) and wild-
type control (ERp57WT) MEFs were transfected with a construct for PrPC-3F4. After 16 h, a radioactive pulse 
was conducted with 0.10 mCi of 35S-Promix per plate. The chase of PrP protein was performed from 10 to 180 
min. Then cells were lysed and PrP purified by immunoprecipitation using anti-PrP (3F4) antibody. Samples 
were analyzed in 12% SDS-PAGE gels under thiol reducing (+DTT, upper panel) and non-reducing (-DTT, 
lower panel) conditions and revealed by autoradiography. White, gray, and black arrowheads indicate di-, mono-
, and non-glycosylated forms of PrP, respectively. The asterisk indicate higher molecular weight forms of PrP 
containing more complex glycosylations. (B) Deglycosylation analysis of PrPC in MEFs after treatment of 
protein extracts with PNGase F. The different glycosylation states of PrP are identified as in (A). (C) Filter-tap 
analysis of aggregates of endogenous PrPC in ERp57-deficient and control MEFs under basal conditions. Dot-
blot on PVDF membrane followed by Ponceau S staining or Western blot analysis of Hsp90 and PrP were 
performed as loading controls. Bands were cropped from their original position for the clarity of presentation. 
All samples were run in the same electrophoresis and detected in the same Western blot. (D) Thiol reduction 
assay using dithiothreitol (DTT) was performed to determine the dependence of PrPC aggregates on disulfide 
crosslinks using filter-trap analysis. Dot-blot on PVDF membrane followed by Ponceau S staining used as 
loading control. (E) ERp57-deficient and wild-type MEFs were transfected with constructs for PrPC-GFP or 
APP-GFP. After 48 h, cells were treated with 50 g/ml cycloheximide (CHX) for the indicated time points and 
fluorescence intensity measured by flow cytometry. The initial fluorescence was normalized to one unit for 
control cells to monitor relative protein decay over time. Data represents the average and standard error of three 
independent experiments. Statistical analysis was performed using two-way ANOVA with Bonferroni post hoc 
test. Mean ± SEM shown; **, p ≤ 0.01. 
 
FIGURE 5. Immunoprecipitation of PrP with ERp57 and PDIA1. (A) HEK293T cells were co-transfected 
with expression vectors for V5-tagged PDIA1, ERp57 or ERp72 together with 3F4-tagged PrPC. After 48 h, V5-
tagged proteins were immunoprecipitated (IP) and eluted with V5 peptide. The possible interaction of PDIs with 
PrP was analyzed by Western blot using anti-PrP (3F4) and anti-V5 antibodies. Hsp90 was monitored as a 
loading control. The inputs and elutions (IP: V5) are shown. (B) HEK 293T cells were co-transfected with 
expression vectors for V5-tagged ERp57 together with 3F4-tagged PrPC or PrPD177N. After 48 h, V5-tagged 
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proteins were immunoprecipitated and eluted with V5 peptide. The possible interaction of ERp57 with PrP was 
analyzed by Western blot using anti-PrP (3F4) and anti-V5 antibodies. The inputs and elutions (IP: V5) are 
shown.  
 
FIGURE 6. Effect of ERp57 expression on ER stress responses. (A) ERp57WT and ERp57KO MEFs were 
treated with the ER stressor tunicamycin (Tm) for 16 h and the levels of indicated ER chaperones and cofactors 
were measured by Western blot analysis. Hsp90 was employed as a loading control. (B) ERp57WT and ERp57KO 
MEFs were treated or not with tunicamycin (Tm), Thapsigargin (Thg), or Brefeldin A (Bref A), and cell viability 
assessed 16 h later by the MTT assay. Data represents mean and standard deviation of three measurements. (C) 
NSC34 cells transiently overexpressing V5-tagged ERp57 and Mock control were treated with tunicamycin 
(Tm) for the indicated time points. ER stress responses were assessed by monitoring the levels of XBP1 spliced 
(Xbp1s) and unspliced (Xbp1u) mRNAs, in addition to Chop mRNA levels by semi-quantitative RT-PCR. Actin 
was used as housekeeping control. (D) NSC34 cells overexpressing V5-tagged ERp57 and Mock control cells 
were treated with the ER stressor tunicamycin (Tm) for 16 h and the level of indicated ER folding components 
measured by Western blot analysis. Hsp90 was employed as a loading control. (E) NSC34 cells overexpressing 
V5-tagged ERp57 and Mock control cells were treated with tunicamycin (Tm) or Thapsigargin (Thg) and cell 
viability assessed 16 h later by the MTT assay. Data represents mean and standard deviation of three 
measurements. 
 
FIGURE 7. Endogenous PrP levels on a conditional knockout mice for ERp57. (A) Erp57 floxed animals 
were crossed with Nestin-Cre transgenic mice to generate CNS-specific knockout and heterozygous animals. 
The expression levels of ERp57 were evaluated by quantitative real-time PCR in brain cortex tissue of control 
(ERp57WT), heterozygous (ERp57HET), and homozygous (ERp57cKO) animals. (B) ERp57 levels were analyzed in 
mice of all three genotypes by Western blot of brain cortex, hippocampus, and cerebellum. As a loading control, 
β-actin levels were determined. (C) The level of PrP mRNA was determined by real-time PCR in brain cortex of 
all three genotypes. (D) PrP levels were analyzed by Western blot using the anti-PrP (6D11) antibody in cortex 
tissue of ERp57WT (n = 4), ERp57HET (n = 4), and ERp57cKO (n = 4) animals. ERp57 levels were also determined. 
β-actin levels were measured as loading control. (E) PrP bands were quantified by densitometric analysis using 
the ImageJ program. Di-glycosylated (left panel), mono-glycosylated (middle panel), and non-glycosylated 
(right panel) forms of endogenous PrP were quantified and normalized to the loading control. (F) Expression 
levels of Bip, Edem1, Pdia1, and Chop mRNA were determined in the cortex of ERp57WT, ERp57HET, and 
ERp57cKO animals by real-time PCR. All values were normalized to Actin mRNA. (G) The levels of indicated 
ER folding components were determined in the cerebellum of ERp57WT, ERp57HET, and ERp57cKO animals by 
Western blot. β-actin was employed as a loading control. (H) Immunofluorescence against NeuN (red) and 
GFAP (green) to visualize the content of total neurons and astrocytes, respectively, in spinal cord ventral horn (n 
= 5). Statistical analyses were performed using one-way ANOVA and Bonferroni Multiple Comparison Test. 
Mean ± SEM shown; p values: n.s., p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
 
FIGURE 8. Endogenous PrP levels in animals overexpressing ERp57 in the CNS. A neuronal-specific 
Erp57 transgenic mouse was generated using the PrP promoter to drive ERp57-FLAG expression. (A) ERp57 
protein levels were evaluated in the cerebellum of ERp57 transgenic mice (n = 4) compared to non-transgenic 
littermates (n = 4) by Western blot analysis. β-actin was used as loading control. (B) Immunohistochemistry to 
ERp57 was also employed to confirm overexpression of the human protein in brain cortex of transgenic mice 
compared to non-transgenic littermates. Scale bar represents 20 µm. (C) Endogenous PrP levels were assessed in 
the cerebellum of ERp57 transgenic animals (n = 3) compared to non-transgenic littermates (n = 3). Anti-PrP 
(6D11) antibody was used for Western blot detection. β-actin was used as loading control. Densitometric 
analysis of PrP levels is shown in the right panel. (D) The level of PrP mRNA in cerebellum of ERp57 
transgenic animals was determined by real-time PCR. (E) The levels of Xbp1s and Chop mRNA were 
determined by real-time PCR in brain cortex of ERp57 transgenic mice and non-transgenic littermates injected 
intraperitoneally with 1 g of the ER stressor tunicamycin (Tm) per gram of body weight or vehicle (150 mM 
glucose). All values were normalized to actin mRNA (n = 3). Statistical analyses were performed using 
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Student’s t-test in panel (C) and one-way ANOVA with Bonferroni Multiple Comparison Test in (E). Mean ± 
SEM shown; p values: n.s., p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
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